- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03781375
Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis
A Phase III Double Blind Randomized Study Comparing Etanercept (Enbrel) Combined With Methotrexate vs Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Patients must have had a diagnosis of JRA by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular
- Disease course must have been polyarticular with at least 5 active joints
- Duration of disease was not limited, but must have been long enough for the patient to have been given a 3-month trial of non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate at a dose between 0.3 and 1.0 mg/kg/week, orally (PO) or subcutaneously (SC)
- Receiving methotrexate at a dose between 0.3 mg/kg/wk and 1 mg/kg/wk at time of randomization. The dose of methotrexate must have been stable for one month prior to entry
- Patients may have failed prednisone, or been on a dosage of prednisone not to have exceeded 10 mg/day or 0.20 mg/kg/day (whichever was less)
- At the time of qualification (screening) for study and prior to wash-out of all disease modifying anti-rheumatic drugs (DMARDs), the patient must have had active disease, defined as ≥ 5 swollen joints accompanied by pain, and/or tenderness and/or warmth, and ≥ 3 joints with limitation of motion (LOM). (The joints with LOM may have been the same as those with swelling)
- Had good venous access and stable hematocrit ≥ 24 mL/dL
- Patients must have been pre-pubescent, or if post-pubertal at anytime during the study, and of child-bearing potential, must have been practicing adequate contraception
- Parent or legal guardian was able and willing to give informed consent
- Parent or legal guardian must have been willing to actively supervise storage and administration of study drug and ensure that the date and time of each dose was accurately recorded in the subject's diary
Exclusion Criteria:
- Was unable to meet the concurrent medication restrictions as described in the protocol
- Pregnant or nursing female
Patients were excluded if they demonstrated clinically significant deviations from normal (as defined below) in any of the following laboratory parameters:
- thrombocytopenia; platelet count < 100,000/cmm
- leukopenia; total white cell count < 4000 cells/cmm
- neutropenia; neutrophils < 1000 cells/cmm
- hepatic transaminase levels > two times the upper limit of normal (ULN)
- serum bilirubin > two times the ULN
- estimated creatinine clearance of < 90 mL/min/1.73 M² body surface area (BSA)
- known human immunodeficiency virus (HIV), hepatitis B surface antigen positivity not related to vaccination, or hepatitis C antibody positivity
- Had received etanercept, antibody to tumor necrosis factor (TNF) (i.e. infliximab or D2E7), antibody to cluster of differentiation (CD)4 (anti-CD4), diphtheria interleukin (IL)-2 fusion protein (DAB-IL-2) or leflunomide
- Had received DMARDs including D-penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin, azathioprine; intravenous immunoglobulin (IV Ig); or broadly immunosuppressant chemotherapeutic agents (e.g. cyclophosphamide, FK506, mycophenolate mofetil [CellCept]), for at least 28 days prior to enrollment and dosing of study drug. All DMARDs, other than methotrexate, must have been washed-out for a minimum of 28 days
- Had received intraarticular glucocorticoid injection within 28 days prior to enrollment on study
- Had previously received live virus vaccine within 3 months prior to study entry
- Had participated in a study of an investigational drug or biologic requiring informed-consent within three months prior to study entry
- Any concurrent medical condition which would have, in the investigator's opinion, compromised the patient's ability to tolerate the study drug or would have made the patient unable to cooperate with the protocol
- History of/or current psychiatric illness that would have interfered with ability to comply with protocol requirements or give informed consent
- Chronic or recurrent infections, or currently active infection at screening
- History of alcohol or drug abuse that would have interfered with ability to comply with protocol requirements
- Inability to have complied with the study requirements
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Methotrexate + Placebo
Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months.
After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
|
Administreres ved subkutan injeksjon to ganger i uken
Andre navn:
Administered by subcutaneous injection twice a week
Administered orally or subcutaneously once a week at the same dose as prior to study entry
|
Eksperimentell: Methotrexate + Etanercept
Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months.
After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
|
Administreres ved subkutan injeksjon to ganger i uken
Andre navn:
Administered orally or subcutaneously once a week at the same dose as prior to study entry
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With a JRA Response at Month 6
Tidsramme: Baseline and month 6
|
Response was defined using the JRA definition of improvement (JRA DOI) as a ≥ 30% improvement from baseline in at least three of the six JRA Core Set Criteria and ≥ 30% worsening in not more than one of the six assessments. The JRA Core Set Criteria consist of:
|
Baseline and month 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With a 50% Improvement in JRA DOI at Month 6
Tidsramme: Baseline and month 6
|
Response was defined using the JRA definition of improvement (JRA DOI) as a ≥ 50% improvement from baseline in at least three of the six JRA Core Set Criteria and ≥ 30% worsening in not more than one of the six assessments. The JRA Core Set Criteria consist of:
|
Baseline and month 6
|
Percentage of Participants With a 70% Improvement in JRA DOI at Month 6
Tidsramme: Baseline and month 6
|
Response was defined using the JRA definition of improvement (JRA DOI) as a ≥ 70% improvement from baseline in at least three of the six JRA Core Set Criteria and ≥ 30% worsening in not more than one of the six assessments. The JRA Core Set Criteria consist of:
|
Baseline and month 6
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Autoimmune sykdommer
- Leddsykdommer
- Muskel- og skjelettsykdommer
- Revmatiske sykdommer
- Bindevevssykdommer
- Leddgikt
- Leddgikt, revmatoid
- Leddgikt, Juvenile
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystemet
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Gastrointestinale midler
- Dermatologiske midler
- Reproduktive kontrollmidler
- Abortfremkallende midler, ikke-steroide
- Aborterende midler
- Folsyreantagonister
- Etanercept
- Metotreksat
Andre studie-ID-numre
- 20021628
- 016.0028 (Annen identifikator: Immunex Corporation)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Juvenil revmatoid artritt
-
University of AarhusAarhus University HospitalFullførtPolyartikulær juvenil revmatoid artritt | Systemisk juvenil idiopatisk artritt | Juvenil idiopatisk artritt, oligoartrittDanmark
-
University of Sao Paulo General HospitalHar ikke rekruttert ennåJuvenil idiopatisk artritt | Juvenil revmatoid artritt | Juvenil leddgiktBrasil
-
Institut National de la Santé Et de la Recherche...FullførtJuvenil idiopatisk artritt med systemisk begynnelseFrankrike
-
NovartisFullførtLeddgikt, juvenil revmatoidItalia
-
SightGlass Vision, Inc.Aktiv, ikke rekrutterendeNærsynthet | Juvenil MyopiForente stater, Canada
-
SightGlass Vision, Inc.Fullført
-
Novartis PharmaceuticalsFullførtSystemisk juvenil idiopatisk artritt (SJIA)Italia, Den russiske føderasjonen, Tyrkia, Belgia, Spania, Tyskland, Frankrike, Israel, Canada, Forente stater, Ungarn, Østerrike, Brasil, Sverige, Nederland, Polen
-
Boston Children's HospitalThe Hospital for Sick Children; Children's Hospital of Philadelphia; University... og andre samarbeidspartnereFullførtJuvenil Osteochondritis DissecansForente stater, Canada
-
GeneScience Pharmaceuticals Co., Ltd.Har ikke rekruttert ennåAktiv systemisk juvenil idiopatisk artrittKina
-
Seattle Children's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases... og andre samarbeidspartnereFullførtJuvenil idiopatisk artritt | Juvenil revmatoid artritt | Juvenil kronisk polyartrittForente stater
Kliniske studier på Etanercept
-
EMSTilbaketrukket
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...FullførtAnkyloserende spondylittKina
-
Shanghai Celgen Bio-Pharmaceutical Co.,LtdUkjentPsoriasis | Plakk PsoriasisKina
-
mAbxience Research S.L.Rekruttering
-
AmgenFullførtLeddgikt, revmatoid; Leddgikt, psoriasisForente stater, Puerto Rico
-
Sun Yat-sen UniversityFullført
-
Samsung Bioepis Co., Ltd.Fullført
-
AmgenFullført
-
AmgenFullført
-
Sun Pharmaceutical Industries LimitedTilbaketrukket